Review decision – May 2016

Review of NICE technology appraisal guidance 278; Omalizumab for the treatment of severe persistent allergic asthma

Decision to move the existing guidance to the static list – May 2016

The Institute was proposing that the guidance should be transferred to the static list.

After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.

Consequently, TA278 will be transferred to the static list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

Review decision paper

This page was last updated: